This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.

Overview and Purpose

The Receptor-Based Therapeutics: An Interactive Exposé symposium will address current areas of debate in the use of biologic therapies for breast cancer. There is a clear need to provide updates on key clinical data in the rapidly evolving field of receptor-based therapeutics in cancer and to place this information in the context of defined clinical situations. In this symposium, emphasis will be given to biologic agents targeting ErbB2 and angiogenic pathways. Treatment options for patients with ErbB2+ metastatic breast cancer will be compared, focusing on issues such as continuing ErbB2-targeted therapy past progression, combinations of targeted agents, and relevant biomarkers. These issues will be addressed through practical case-based presentations and discussions, and recent trial results will be reviewed and integrated into a debate format in which timely or controversial aspects of patient management will be discussed.


Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of breast cancer are also invited to attend.


Learning Objectives

At the conclusion of this symposium, you should be able to:

  • Describe the structure and function of the tyrosine kinase receptors and signaling pathways involved in breast cancer development and progression as well as strategies for therapeutic intervention
  • Compare and contrast treatment options for patients with ErbB2+ metastatic breast cancer, including the continuation of ErbB2-targeted therapy utilizing novel biologic agents
  • Summarize clinical efficacy and safety data on the use of angiogenesis inhibitors in patients with metastatic breast cancer
  • Assess the clinical utility of biomarkers in patient selection for and evaluation of the use of antiangiogenic agents in metastatic breast cancer


CME Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.


Acknowledgement

Supported by an educational grant from
GlaxoSmithKline